|
|
|
Lary A. Robinson, MD, FCCP [BioSketch]
Professor, Director, Division of Cardiovascular
and Thoracic Surgery, H. Lee Moffitt Cancer Center and Research
Institute, University of South Florida, Tampa, FL
Disclosure: No financial relationships
with a commercial party to disclose.
Edward S. Kim, MD [BioSketch]
Associate Professor, Department of Thoracic,
Head, and Neck Medical Oncology, University of Texas, MD Anderson
Cancer Center, Houston, Texas
Disclosure: Dr. Kim has received
research grants from Schering-Plough, Astra Zeneca, and Aventis.
|
|
Overview
Surgical resection has limited success in providing
a cure in non-small cell lung cancer (NSCLC), particularly among
patients with locally advanced disease (stage IIIA). Improved response
rates are more commonly seen with regimens that combine surgery,
radiotherapy, and chemotherapy. However, these modalities have not
been shown to significantly impact survival among patients with
completely resected stage I and II disease. Neoadjuvant cisplatin-based
chemotherapy has already been shown to increase cure rates in stage
IIIA NSCLC from 10 to 15% to 25 to 30%. Radiotherapy, which has
been shown to decrease the rate of local recurrence, may play a
role in advancing cure rates as well. In this edition of Masters
in Medicine, Lary Robinson, MD, FCCP, and Edward Kim,
MD, discuss current modalities and their ability to advance
cure rates in patients with this deadly disease.
Learning Objectives
Upon completion of this
activity, you should be able to:
- Describe the benefits and risks of adjuvant therapy
for patients with non-small cell lung cancer
- Describe the benefits and risks of neoadjuvant
therapy for patients with NSCLC
- Relate the findings of the International Adjuvant
Lung Cancer Trial (IALT) to current treatment plans for patients
with SCLC
Learner Participation to Earn
Credit
To earn a CME certificate, you must:
Computer
Requirements to Participate
Click
here to view the computer requirements to participate in this
activity.
|
| |
Accreditation Statements
Continuing Medical Education for Physicians
The American College of Chest Physicians (ACCP)
is accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for physicians.
The ACCP takes responsibility for the content, quality, and scientific
integrity of this CME enduring activity.
CME Credits
The ACCP designates this educational activity
for a maximum of one (1) category 1 credit toward the AMA Physician's
Recognition Award. Each physician should claim only those credits
that he/she actually spent in the activity.
Only US-licensed physicians will be awarded AMA PRA
category 1 credit. All others, including international-licensed
physicians, will receive a certificate of course completion.
Accreditation Period
This program was initially published on February 12, 2004, and is
eligible for credit through December 31, 2005.
Disclosure Statement
As a sponsor accredited by ACCME, the ACCP must ensure balance,
independence, objectivity, and scientific rigor in all its individually
sponsored and jointly sponsored educational activities. All faculty
participating in this activity are expected to disclose to the activity
audience any or no significant financial interest or other relationship
(1) with the manufacturer(s) of any commercial product(s) and/or
provider(s) of commercial services discussed in an educational presentation,
and/or (2) with any commercial supporters of the activity. It remains
for the audience to determine whether the speaker's interests or
relationships may influence the presentation with regard to exposition
or conclusion. Disclosure of any or no relationships will be made
available during this activity.
|
|
|
Course Certificate Fees
This course certificate is FREE to
qualified attendees.
|
|
|
